(Q36180596)

12 August 2017

1 reference

title

Chronic graft-versus-host disease: where is promise for the future? (English)

1 reference

12 August 2017

Weisdorf DJ

1

1 reference

12 August 2017

publication date

1 September 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

19

1 reference

12 August 2017

issue

9

1 reference

12 August 2017

page(s)

1532-1535

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403856

12 August 2017

exact match

0 references

cites work

Chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

A survey of diagnosis, management, and grading of chronic GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis i

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Optimistic expectations and survival after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Chronic graft-versus-host disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Development of a prognostic model for grading chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Chronic graft-versus-host disease: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

How I treat chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

7 January 2021

Response to thalidomide therapy in refractory chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

7 January 2021

Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

7 January 2021

Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

7 January 2021

Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

7 January 2021

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403856

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403856

1 reference

12 August 2017

1 reference